日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Reduced Weight Gain with Pioglitazone vs Vildagliptin in CREBRF rs373863828 A-allele Carriers: Insights from the WORTH Trial

在CREBRF rs373863828 A等位基因携带者中，吡格列酮与维格列汀相比可减少体重增加：来自WORTH试验的启示

期刊:Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
影响因子:3
doi:10.2147/DMSO.S500336
Toomata, Zanetta L L; Jiang, Yannan; Yeu, Rui Qian; Brandon, Rebecca; Tweedie-Cullen, Ry Yves; Nehren, Norma; Doherty, Glenn; Watson, Huti; Macaskill-Smith, Kerry A; Leask, Megan; Merriman, Tony R; Paul, Ryan; Merry, Troy L; Shepherd, Peter R; Murphy, Rinki
CREB
发表日期：2025
文献求助 收藏

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial

在一项随机交叉试验中，根据肥胖和高甘油三酯血症对维格列汀和吡格列酮的降血糖反应进行分层分析

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2022.1091421
Brandon, Rebecca; Jiang, Yannan; Yeu, Rui Qian; Tweedie-Cullen, Ry; Smallman, Kate; Doherty, Glenn; Macaskill-Smith, Kerry A; Doran, Rebekah J; Clark, Penny; Moffitt, Allan; Merry, Troy; Nehren, Norma; King, Frances; Hindmarsh, Jennie Harré; Leask, Megan Patricia; Merriman, Tony R; Orr-Walker, Brandon; Shepherd, Peter R; Paul, Ryan; Murphy, Rinki
肥胖
代谢
发表日期：2022
文献求助 收藏